Warning that a rash increase could lead to a "catastrophe," Mr. Zangeneh said OPEC nations "must move with the market and seek stability.
The most frequently reported AEs were increased alanine aminotransferase and aspartate aminotransferase, followed by rash, increased blood bilirubin and diarrhoea.
Side effects have included a rash, increased urinary frequency and nocturnal enuresis, and occasional mild fevers with no known source.
Adverse events in five patients led to treatment discontinuation (eye pruritus; eye irritation; increased blood pressure and rash; increased blurred vision; deepening of the eyelid sulcus and blepharoptosis).
She also reported having a rash, increasing fatigue, nausea, and vomiting, disabling her to the point where she could no longer work full-time.
AEs were generally manageable and grade 3 to 4 AEs occurred in 3 patients, including rash, increased transaminase, and hyperglycemia [ 66].
The most common toxic side effects are skin rash, increase in transaminases and creatinine, and gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain.
Overall, 5 adverse drug reactions to micafungin were reported during the study period: 4 were classified as non-serious (anemia, rash, increasing bilirubin and exacerbation of pre-existing tremor) and 1 was serious (increase of liver enzymes).
The most frequent AEs were increased alanine aminotransferase and increased aspartate aminotransferase, followed by rash, increased blood bilirubin and diarrhoea; these were similar to AEs seen with other inhibitors of the EGFR family of tyrosine kinases (Hidalgo et al, 2001; Herbst et al, 2002; Ranson et al, 2002; Arora and Scholar, 2005; Lacouture et al, 2006).
Adverse drug reactions leading to treatment discontinuation were anemia, rash, increasing bilirubin in a patient with pre-existing liver disease due to chronic HCV-related hepatitis and primary biliary cirrhosis, and severe hepatic failure, defined by an increase in liver enzymes plasmatic values with a concomitant reduction of prothrombin time.
